MOH · Molina Healthcare, Inc.

Current Thesis

Molina Healthcare’s recovery case rests on improving Medicaid profitability; reclaiming the $205 breakout reference and preserving the earnings floor at the 2026-10-21 results would confirm the next leg. The company raised its full-year 2026 adjusted earnings per share (EPS) guidance to at least $5.25 on 2026-07-22. That remains the fundamental anchor, rather than proof that the recovery has arrived. Company results release.

The September refresh shows improved momentum without a price breakout. The supplied adjusted series records a $200.79 close on 2026-09-18, versus $200.80 on 2026-09-04; the 14-day relative strength index (RSI) rose to 50.7 from 46.2 across those observations. The narrative is maturing — the July guidance improvement remains its anchor, while the September 18 close remains below the $205 breakout-gap reference identified in the September 5 research note. This is an inference from the dated results and price observations, not a measurement of investor flows.

The case remains low-conviction because price has not reclaimed that reference and Marketplace profitability remains unresolved. A weekly close below $188 would invalidate the price-recovery thesis; a reduction of the July earnings floor would independently break its fundamental premise.

Bullish and bearish views on Molina Healthcare, Inc.

The model's bull view on Molina Healthcare, Inc. (MOH), in brief: The earnings floor increased. Molina’s 2026-07-22 release raised full-year adjusted EPS guidance by $0.25 to at least $5.25 and reported second-quarter adjusted EPS of $1.51. Company results release. Medicaid supported the guidance increase. The 2026-07-22 release attributed the… The bear view: Marketplace offset Medicare’s improvement. Both cases follow in full.

Bull Case

• The earnings floor increased. Molina’s 2026-07-22 release raised full-year adjusted EPS guidance by $0.25 to at least $5.25 and reported second-quarter adjusted EPS of $1.51. Company results release.
• Medicaid supported the guidance increase. The 2026-07-22 release attributed the increase to first-half Medicaid performance. Management described the rate-versus-cost imbalance as stabilizing; that is management’s assessment, with subsequent medical-cost results determining whether it holds. Company results release.
• Momentum improved between dated observations. The adjusted-series RSI reading was 50.7 on 2026-09-18 versus 46.2 on 2026-09-04. That improvement is measured; confirmation of a renewed price-recovery leg still requires a weekly close above the previously identified $205 reference.

Bear Case

• Marketplace offset Medicare’s improvement. Molina’s 2026-07-22 release reported a $1.50-per-share improvement in the full-year Medicare outlook offset by a $1.50-per-share deterioration in Marketplace. The aggregate guidance increase therefore does not establish recovery across all segments. Company results release.
• Price confirmation remains absent. The 2026-09-18 adjusted close of $200.79 remains below the $205 former breakout-gap floor documented in the 2026-09-05 note. The supplied three-month price change is 1.7%; it does not establish an accelerating recovery.
• The latest rating change is limited. PriceTargets records a Weiss Ratings change from D to D+ on 2026-09-11 and Cantor Fitzgerald’s Neutral reiteration on 2026-09-04. Those observations do not establish broad analyst participation. Dated ratings table.

Setup & Price Structure

The market’s 2026-09-18 adjusted close was $200.79, with the supplied series placing it 17.3% below its $242.88 52-week high. The $188–192 support shelf and $205 breakout-gap reference come from the published 2026-09-05 analysis. They remain explicit research thresholds; the supplied update does not include the intervening daily bars needed to verify repeated tests of either zone.

Crowding is unproven. The supplied news record contains a movers roundup dated 2026-09-10 and a historical-return article dated 2026-09-15. That sample is too small to support a retail-attention claim. No current short-interest, trading-volume, moving-average-distance or insider-transaction measurements accompany the September 18 price observations, so neither crowded ownership nor thinning sponsorship can be established.

Catalyst Calendar (next 30 days)

As of 2026-09-19, no company-confirmed event was identified for 2026-09-19 through 2026-10-19. Molina’s published events calendar lists the October earnings call as its next event. Company calendar.

• 2026-10-21 results; 2026-10-22 call. Outside that window, Molina will release third-quarter results after the market close and hold its call the following morning at 8:00 a.m. Eastern Time, according to its 2026-09-02 announcement. This is the next dated test of the July adjusted EPS floor and the medical-cost assumptions supporting recovery. Company scheduling announcement.

What Would Change Our Mind

Loss of the previously identified support shelf would end the price-recovery case: a weekly close below $188 is the observable threshold retained from the 2026-09-05 note. Fundamentally, the 2026-10-21 results would invalidate the trough-recovery premise if Molina reduced full-year adjusted EPS guidance below the at-least-$5.25 floor announced on 2026-07-22.

The positive resolution is also observable: a weekly close above the $205 former breakout reference, accompanied by October results preserving or raising that earnings floor. An improved RSI reading alone does not satisfy those conditions.

Correlation Notes

This is a single-company recovery case; no sector-relative return series or measured peer correlation accompanies the 2026-09-18 observations. Molina’s 2026-07-22 release identifies Medicaid rates and medical-cost trends as the operating mechanism behind management’s recovery argument. Shared managed-care exposure is therefore a plausible source of related price movements, but the available sample cannot establish their strength or direction.